Report overview
This report contains market size and forecasts of Generic Anti-cancer Injectables in Global, including the following market information:
Global Generic Anti-cancer Injectables Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Generic Anti-cancer Injectables market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Bevacizuma Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Generic Anti-cancer Injectables include Teva, Viatris, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Generic Anti-cancer Injectables companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Generic Anti-cancer Injectables Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, by Type, 2021 (%)
Bevacizuma
Rituximab
Herceptin
Paclitaxel
Others
Global Generic Anti-cancer Injectables Market, by Channel, 2017-2022, 2023-2028 ($ millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, by Channel, 2021 (%)
Hospital
Retail
Global Generic Anti-cancer Injectables Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Generic Anti-cancer Injectables Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Generic Anti-cancer Injectables revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Generic Anti-cancer Injectables revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Teva
Viatris
Biocon
Amgen
Sandoz (Novartis)
Pfizer
Qilu Pharmaceutical
Jiangsu Hansoh
CTTQ
Jiangsu Hengrui
CSPC
Innovent Biologics
